MacroGenics Selects 3 Mg/Kg Cancer-Trial Dose, Down From 6 Mg/Kg In Earlier Cohort

The company plans to enroll 20 additional clear cell gynecologic cancer patients by year-end 2026.

Share
MacroGenics Selects 3 Mg/Kg Cancer-Trial Dose, Down From 6 Mg/Kg In Earlier Cohort

MacroGenics, which develops antibody-based cancer medicines, selected a 3 mg/kg dose of lorigerlimab every three weeks, down from 6 mg/kg in an earlier clear cell gynecologic cancer cohort. The company outlined the approach in Friday's SEC disclosure, with the goal of reducing side effects while preserving the experimental drug's effectiveness.

Tumor Responses Came With Toxicity

Interim results presented at ESMO showed confirmed tumor responses in 4 of 16 evaluable patients, or 25%, at the higher dose. But severe treatment-related events affected 8 of 17 patients, or 47%.

Treatment-related side effects led 3 of 17 patients, or 18%, to stop treatment. Those results used a September 1, 2026 cutoff and remain preliminary.

MacroGenics based its dose choice on modeling of how patients are exposed to the drug and its biological activity. Better safety with retained efficacy is the company's objective; the lower-dose cohort is intended to test that approach.

The company plans to enroll 20 additional clear cell gynecologic cancer patients at the selected dose by year-end 2026. Its platinum-resistant ovarian cancer cohort, which included 24 patients at 6 mg/kg every three weeks, is discontinued.

A Difficult Cancer To Treat

Lorigerlimab targets PD-1 and CTLA-4, immune checkpoints, using MacroGenics' DART antibody platform. The company designed it to concentrate CTLA-4 inhibition around tumors while maintaining PD-1 inhibition.

Clear cell gynecologic cancers include ovarian, endometrial and cervical cancers. MacroGenics describes the subtype as poorly represented in larger clinical trials, with limited dedicated drug development.

Amir Jazaeri, vice chair for clinical research in the Department of Gynecologic Oncology at The University of Texas MD Anderson Cancer Center, described the treatment challenge in the corporate presentation: "Clear cell gynecologic malignancies are notoriously aggressive, resistant to conventional platinum-based chemotherapies, and carry a poor prognosis."

Cash Supports Continued Cancer Development

MacroGenics builds its pipeline using proprietary antibody technologies, including antibody-drug conjugates and multispecific antibodies. Lorigerlimab sits within that broader cancer-development business.

The company had $288 million in cash equivalents and marketable securities as of September 30, 2026. Management expects its cash to fund operations through 2028.

MacroGenics plans to provide updated lorigerlimab study results in the first half of 2027.

Sources

More on MacroGenics

All MacroGenics (MGNX) coverage →